Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.2222.

Several analysts have recently commented on BCYC shares. JMP Securities decreased their target price on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating on the stock in a report on Tuesday, August 12th. Morgan Stanley cut their price target on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 12th. Barclays reduced their price objective on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. B. Riley decreased their target price on Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Finally, Oppenheimer reissued an “outperform” rating and set a $44.00 price objective (down previously from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC boosted its stake in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after purchasing an additional 2,345 shares during the period. GAMMA Investing LLC lifted its stake in Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company’s stock worth $76,000 after purchasing an additional 8,065 shares during the last quarter. Ausdal Financial Partners Inc. acquired a new stake in Bicycle Therapeutics in the second quarter valued at about $70,000. Sei Investments Co. bought a new stake in shares of Bicycle Therapeutics during the second quarter worth $74,000. Finally, Virtus Investment Advisers LLC grew its position in Bicycle Therapeutics by 32.6% during the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after acquiring an additional 2,659 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $7.10 on Friday. The company’s fifty day moving average price is $7.71 and its two-hundred day moving average price is $8.63. Bicycle Therapeutics has a one year low of $6.10 and a one year high of $28.67. The company has a market capitalization of $491.68 million, a price-to-earnings ratio of -2.02 and a beta of 1.44.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%. As a group, sell-side analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.